Skip to main content

Advertisement

Table 4 Risk factors for ILD associated with gefitinib use and predictive factors for tumor response in Japanese patients as determined by studies in the literature

From: Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer – a retrospective analysis: JMTO LC03-02

Reference No. patients No. cases ILD (%) No. ILD deaths (%) Risk factors for ILD Response Proportion (%) Predictive factors for tumor response
National Cancer Center, Japan (2004) [20] 112 6
(5.4)
4
(3.6)
-Pre-existing pulmonary fibrosis 33 -No history of smoking
-No history of thoracic radiotherapy
Okayama Lung Cancer
Study Group
(2005) [21]
330 15
(4.5)
8
(2.4)
-PS 2–4
-Pre-existing pulmonary fibrosis
-Prior thoracic irradiation
22 Not investigated
AstraZeneca
(2004) [22]
3322 193
(5.8)
83
(2.5)
-PS 2–4
-History of smoking
-Coexisting IP
-Prior chemotherapy
7.8 Not investigated
West Japan Thoracic
Oncology Group
(2006) [23]
1976 70
(3.5)
31
(1.6)
-History of smoking
-Male
-Coexisting IP
17.6 -PS 0–1
-No history of smoking
-Female
-Adenocarcinoma
-Metastatic disease
AstraZeneca
(2007) [24]
1482 59
(4.0)
ILD-related deaths
In patients with
ILD were 31.6%
-PS 2–4
-History of smoking
-Age >55 years
-Recent NSCLC diagnosis,
-Reduced normal lung on
computed tomography scan
-Preexisting chronic ILD
-Concurrent cardiac disease
Not
investigated
Not investigated
Present study 526 17
(3.2)
7
(1.3)
No factors found to be significant 18.2 -Female
-No previous chemotherapy
-Low absolute neutrophil count
-Adenocarcinoma